By activating GLP-1 receptors, semaglutide helps the pancreas release insulin when needed, lowers glucagon secretion, and slows the movement of food from the stomach into the intestine
Tirzepatide, a dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist, was superior to semaglutide in reducing HbA 1c and body weight in the SURPASS-2 trial, a phase 3, randomised, open-label trial comparing the efficacy and safety of tirzepatide vs semaglutide once weekly as add-on therapy to metformin in individuals with type 2 diabetes [10]
It protects cells from oxidative damage, supports liver detoxification, strengthens the immune system, and contributes to healthy, radiant skin
Gut dysbiosis and increased intestinal permeability (leaky gut) are now considered major contributors to chronic metabolic inflammation
Acute liraglutide attenuated the alcohol-induced increase in accumbal dopamine, decreased alcohol-induced CPP, and prevented alcohol deprivation-induced drinking